INmune Bio secures long-term umbilical cord supply for CORDStrom MSC platform via Anthony Nolan agreement

Inmune Bio, Inc.

AN granted exclusive license to use donor materials; INmune Bio added as party with joint liability for royalty payments.
AN receives 2% royalty on net sales of each product, capped at £5M annually; £400+VAT fees per cord tissue, CPI-adjusted annually.
Term runs until 10 years after first commercial sale; either party may terminate with 30 days (IMB/INMB) or 6 months (AN) notice.
Pipeline targets RDEB, CORDStrom-col7a, CORDStrom-TRAIL (oncology), osteoarthritis, and systemic lupus erythematosus (SLE).
Materials handled per GMP and HTA standards; enables global regulatory compliance (FDA, EMA, MHRA).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Inmune Bio, Inc. entered into Amended and Restated Material Transfer and License Agreement with Anthony Nolan valued at an annual cap of £5,000,000 (effective 2026-04-29).

Action: entry
Agreement: license
Counterparty: Anthony Nolan
Value: an annual cap of £5,000,000
Effective: 2026-04-29

Exact text from the filing

On April 29, 2026, INmune Bio Inc. (the “Company”) entered into an amended and restated Material Transfer and License Agreement (the “ Amended and Restated Agreement ”) with INmune Bio International (“ IMB ”), a company incorporated in England and the Company’s wholly-owned subsidiary, and Anthony Nolan (“ AN ”), a company limited by guarantee incorporated in England, which amended and restated the original agreement signed by IMB and AN on November 29, 2017, as amended and restated on March 21, 2023 (the “ Original Agreement ”).

View on SEC.gov

Browse all material agreements →

Inmune Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-052231

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.